ArticleBMC nephrology2017
Factors affecting the long-term outcomes of idiopathic membranous nephropathy.
Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy.Renal failure · 2023Trial
- A New Perspective on Predicting PLA2R-Associated Membranous Nephropathy Relapse: The Value of a Genetic Risk Score.Journal of inflammation research · 2026Article
- The level and clinical significance of serum soluble M-type phospholipase A2 receptor in patients with primary membranous nephropathy.Renal failure · 2025Article
- Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.Kidney international reports · 2025Article
- Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management.Frontiers in immunology · 2025Review
- Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.Renal failure · 2024Article
- Prognostic factors affecting long-term outcomes in patients with concurrent IgA nephropathy and membranous nephropathy.Heliyon · 2024Article
- A Dynamic Prediction Model for Renal Progression in Primary Membranous Nephropathy.International journal of medical sciences · 2024Article
- Glomerulosclerosis is a prognostic risk factor in patients with membranous nephropathy and non-nephrotic proteinuria.Renal failure · 2023Article
- From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?Journal of nephrology · 2023Review
- Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis.Archives of medical science : AMS · 2023Review
- Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients.Therapeutics and clinical risk management · 2023Article
- Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.Renal failure · 2022Article
- Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.The Korean journal of internal medicine · 2022Review
- Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis.Applied bionics and biomechanics · 2022Review
- Autoimmune-mediated renal disease and hypertension.Clinical science (London, England : 1979) · 2021Review
- Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: a retrospective analysis of 217 cases.Journal of nephrology · 2021Article
- Glomerulosclerosis predicts poor renal outcome in patients with idiopathic membranous nephropathy.International urology and nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe attempted to describe the clinical features and determine the factors associated with renal survival in idiopathic membranous nephropathy (iMN) patients with nephrotic syndrome (NS) and to determine the factors associated with spontaneous complete remission (sCR) and progression to NS in iMN patients with subnephrotic proteinuria.
methodsThis retrospective study involved 166 iMN patients with NS and 65 patients with subnephrotic proteinuria. The primary end point was a doubling of serum creatinine or initiation of dialysis. In patients with subnephrotic proteinuria, we determined the factors associated with sCR and factors associated with progression to NS.
resultsRemission of NS was achieved in 125 out of 166 patients (75.3%). Of those who reached remission, 26 patients (20.8%) experienced relapse that was followed by second remission. The relapse or persistence of proteinuria was associated with the primary end points (hazard ratio [HR] = 12.40, P = 0.037, HR = 173, P < 0.001, respectively). In patients with subnephrotic proteinuria, sCR occurred in 35.4% of the patients. The patients with sCR had lower proteinuria and serum creatinine levels and higher serum albumin concentrations at baseline. The serum albumin level at diagnosis was a prognostic factor for progression to NS (Odds ratio [OR] = 0.015, P < 0.001).
conclusionsThe occurrence of relapse or persistence of proteinuria had negative effects on renal survival in iMN patients with NS, and low serum albumin levels at baseline were associated with non-achievement of sCR and progression to NS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.